Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.6989 | 0.6307 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.1847 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.6989 | 0.6307 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0023 | 0.1847 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.6989 | 0.6307 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.1847 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0023 | 0.1847 | 1 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.1847 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1847 | 0.5 |
Brugia malayi | hypothetical protein | 0.0043 | 0.6989 | 0.6307 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.1847 | 0.5 |
Leishmania major | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.6989 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.6989 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.6989 | 0.6307 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.6989 | 1 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0023 | 0.1847 | 0.5 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.1847 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0023 | 0.1847 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.6989 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.3548 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 0.8913 uM | PubChem BioAssay. qHTS of Nrf2 Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.5821 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.